Search bioRxiv⌕ Search

Biology subjects

Panov, K.

Publications and source records attributed to Panov, K..

5 recordsLinked to original sources

Genome-wide loss of chromatin accessibility coexists with selectively elevated RNA abundance in nutrient-starved U2OS cells

Background Chromatin accessibility is widely used as a proxy for regulatory potential and is often interpreted together with RNA-seq to infer gene-regulatory responses. However, the quantitative relationship between chromatin accessibility and transcript abundance may become difficult to interpret, particularly under acute cellular stress. Metabolic challenges such as nutrient deprivation are known to induce extensive chromatin remodelling and transcriptional reprogramming, raising the question of whether changes in transcript abundance are directly governed by chromatin accessibility in these contexts. Clarifying this relationship is critical for interpreting epigenomic data under stress conditions, and requires careful distinction between Tn5 accessibility, relative steady-state RNA abundance and transcriptional output. Results We integrated ATAC-seq and RNA-seq analyses in human U2OS osteosarcoma cells following 18 h of severe nutrient deprivation. We found that starvation was associated with a genome-wide reduction in accessibility and almost all significantly altered accessible regions showed reduced signal relative to actively growing cells. This decrease affected promoter- and enhancer-associated regions alike, including housekeeping-gene promoters and CTCF-motif sites. In contrast, RNA-seq revealed a more selective change in relative steady-state RNA abundance: only a minority of expressed genes were differentially regulated, and approximately 64% of differentially expressed genes showed increased relative RNA abundance. Changes in accessibility and transcript abundance were modestly correlated at promoters (Pearson r = 0.25) and weakly at enhancers (r = 0.10), and together explained only ~6% of the variance in transcript abundance changes. The relationship was graded: genes with the smallest promoter losses were about four times as likely to show increased RNA abundance as genes with the largest losses, independently of baseline promoter accessibility. Within-condition analyses similarly showed only modest relationships between promoter accessibility and RNA abundance in both actively growing and starved cells. Pathway-level analysis of mRNA abundance revealed the expected repression of biosynthetic and growth-related programmes, including ribosome biogenesis, translation and cellular growth, together with a less anticipated relative activation of stress-adaptive programmes, including extracellular matrix organisation, lipid and cholesterol metabolism, small GTPase signalling and developmental processes. For genes within these activated programmes, increased steady-state mRNA abundance was observed despite reduced ATAC-seq accessibility at associated regulatory regions. Exon-intron analyses of RNA-seq data indicated that these changes predominantly reflect altered RNA production. Metabolic labelling of nascent RNA at selected loci confirmed increased transcription of genes involved in adaptive programmes despite reduced promoter and enhancer accessibility, alongside with reduced production of biosynthetic transcripts and rRNA. Conclusions These findings demonstrate that chromatin accessibility and steady-state RNA abundance are only modestly coupled during severe nutrient deprivation, against a baseline of similarly modest promoter accessibility-abundance coupling. This underscores the limited ability of ATAC-seq accessibility to predict transcript abundance under this stress condition and supports a model in which chromatin accessibility acts as a permissive rather than deterministic layer of gene regulation. The selective induction of adaptive programmes, confirmed here at the level of RNA production, shows that transcriptional activation can occur despite genome-wide loss of ATAC-seq accessibility. Because ATAC-seq reports Tn5 accessibility rather than physical chromatin compaction, we interpret compaction as a plausible mechanistic model compatible with the current observations, which will require direct orthogonal validation.

bioinformatics↗

Novel RNA Polymerase I and Cyclin Dependent Kinase combination therapy for the treatment of aggressive Acute Myeloid Leukemia.

Despite advances in therapy, specific subtypes Acute Myeloid Leukaemia (AML) remains largely incurable. The first-in-class RNA Polymerase I (Pol I) inhibitor, CX-5461, has demonstrated promising activity in both haematological malignancies and solid tumours by selectively inhibiting ribosome biogenesis to induce nucleolar stress, a critical vulnerability in rapidly proliferating cancer cells. CX-5461 has undergone clinical trials for the treatment of both solid and haematological malignancies, and 2nd generation Pol I inhibitor PMR-116 has also entered clinical trials, underscoring the translational potential of drugs that target RNA Polymerase I. To enhance the therapeutic efficacy of Pol I inhibition and prevent the emergence of resistance, we conducted a cell line-based unbiased screen of FDA-approved drugs to identify compounds that might synergise with CX-5461. This screen revealed that the pan-CDK inhibitors Dinaciclib and Flavopiridol enhance nucleolar stress pathway (NSP) activation and are strong candidates for combinatorial therapy with CX-5461. Further analysis showed that the combination of CX-5461 and Dinaciclib acts synergistically across a genetically diverse panel of human AML cell lines. This synergy is dependent on an intact NSP, with both agents independently stabilising p53, but with distinct phenotypic outcomes: Dinaciclib induces rapid apoptosis, whereas CX-5461 primarily enforces cell cycle arrest. This functional complementarity results in efficient tumour cell clearance and likely accounts for the delayed onset of therapy resistance. Importantly, combination treatment with CX-5461 and Dinaciclib significantly improved survival in murine models of AML and reduced colony formation in primary human AML samples. Together these findings provide preclinical evidence for a novel combination treatment strategy that leverages nucleolar stress and cell cycle control to enhance treatment outcomes in AML, paving the way for clinical translation of Pol I-CDK co-targeting therapies.

cancer biology↗

The novel RNA polymerase I transcription inhibitor PMR-116 exploits a critical therapeutic vulnerability in a broad-spectrum of high MYC malignancies.

Ribosome biogenesis (RiBi) is a key determinant of cell growth and proliferation and is highly elevated in cancer due to the activation by oncogenes such as MYC. First-generation RiBi inhibitor CX-5461, while demonstrating clinical potential for cancer treatment, also induces DNA damage through off-target inhibition of TOP2 and potentially other mechanisms, bringing into question RiBi as a target for cancer therapy. In this study, we test second-generation RiBi inhibitor, PMR-116. PMR-116 exhibits improved drug-like properties compared to first-generation RiBi inhibitors and has robust anti-tumour activity in the absence of global DNA damage signalling in a broad range of pre-clinical models of haematologic and solid cancers, particularly in malignancies where MYC is either the driver of disease or is elevated. Thus, our work demonstrates that RiBi is a genuine target for cancer therapy and highlights the potential to exploit a critical therapeutic vulnerability in high-MYC human cancers with dismal therapeutic outcomes. Statement of significanceDespite the development of new cancer therapies, most advanced malignancies remain incurable. We demonstrate that PMR-116, a second-generation RiBi inhibitor, has robust therapeutic efficacy in preclinical models of cancer, offering great promise to treat a broad spectrum of human solid and haematologic malignancies, especially where MYC is a driver.

cancer biology↗

The human RNA polymerase I structure reveals an HMG-like transcription factor docking domain specific to metazoans

Transcription of the ribosomal RNA precursor by RNA polymerase (Pol) I is a major determinant of cellular growth and dysregulation is observed in many cancer types. Here, we present the purification of human Pol I from cells carrying a genomic GFP-fusion on the largest subunit allowing the structural and functional analysis of the enzyme across species. In contrast to yeast, human Pol I carries a single-subunit stalk and in vitro transcription indicates a reduced proofreading activity. Determination of the human Pol I cryo-EM reconstruction in a close-to-native state rationalizes the effects of disease-associated mutations and uncovers an additional domain that is built into the sequence of Pol I subunit RPA1. This dock II domain resembles a truncated HMG-box incapable of DNA-binding which may serve as a downstream-transcription factor binding platform in metazoans. Biochemical analysis and ChIP data indicate that Topoisomerase 2a can be recruited to Pol I via the domain and cooperates with the HMG-box domain containing factor UBF. These adaptations of the metazoan Pol I transcription system may allow efficient release of positive DNA supercoils accumulating downstream of the transcription bubble.

biochemistry↗

Functional microRNA targetome undergoes degeneration-induced shift in the retina

MicroRNA (miRNA) play a significant role in the pathogenesis of complex neurodegenerative diseases, including age-related macular degeneration, acting as post-transcriptional gene suppressors through their association with argonaute (AGO) protein family members. However, to understand their role in disease, investigation into the regulatory nature of miRNA with their targets is required. To identify the active-miRnome-targetome interactions in the degenerating retina, AGO2 HITS-CLIP was performed using a mouse model of retinal degeneration. Analysis revealed a similar miRnome between healthy and damaged retinas, however, a shift in the active targetome was observed. This shift was also demonstrated by a change in the seed binding regions of miR-124-3p, the most abundant retinal miRNA loaded in AGO2. Following damage, AGO2 was localised to the inner retinal layers indicating a locational miRNA response to retinal damage. This study provides important insight into the alteration of miRNA regulatory activity that occurs as a response to retinal degeneration.

molecular biology↗